UK pharma industry signs landmark deal with government health service over drug prices

Eng­land’s Na­tion­al Health Ser­vice and the phar­ma in­dus­try on Mon­day morn­ing an­nounced a new five-year deal that will save the NHS £14 bil­lion ($17.4 bil­lion) in drug costs, but al­so dou­ble the an­nu­al al­lowed growth of brand­ed med­i­cines be­tween 2024 and 2027.

The agree­ment, which runs from 2024 through the end of 2028, sets a year­ly cap on the to­tal al­lowed sales val­ue of brand­ed med­i­cines to the NHS each year. Sales above the cap are paid back to the gov­ern­ment via a levy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.